Drug or treatment

Nimotuzumab clinical trials

• 21Clinical trials
• 2Countries

Newest trials

All recruiting trials (21)

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

• Neoadjuvant chemoradiotherapy with serplulimab and nimotuzumab for resectable locally advanced esophageal squamous cell carcinoma

  This trial will try adding serplulimab and nimotuzumab to preoperative chemoradiotherapy to see if it improves surgical and pathological outcomes for adults with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07457528

• Postoperative radiotherapy with nimotuzumab followed by bemcentinib for high-risk head and neck cancer patients who can't take cisplatin

  This study will see if adding nimotuzumab during postoperative radiotherapy followed by bemcentinib can help prevent recurrence in high-risk head and neck cancer patients who are unable to receive cisplatin.

  Recruiting Phase 3 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai · NCT07445048

• Nimotuzumab plus toripalimab and chemotherapy for locally advanced tonsillar cancer

  This trial will try giving nimotuzumab and toripalimab together with chemotherapy before surgery to see if it increases complete tumor response in people with resectable, locally advanced tonsillar cancer.

  Recruiting Phase 2 Tang-Du Hospital · Shanxi, Province · NCT07353723

• Radiotherapy with nimotuzumab versus radiotherapy alone for platinum-ineligible advanced head and neck squamous cell carcinoma

  This trial tests whether adding nimotuzumab to radiotherapy helps people with advanced head and neck squamous cell carcinoma who cannot receive platinum chemotherapy.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Shandong, Province · NCT07333274

• HRS-4642 plus nimotuzumab and chemotherapy for borderline resectable pancreatic cancer with KRAS G12D

  This Phase II trial will test whether adding HRS-4642 and nimotuzumab to gemcitabine and albumin-bound paclitaxel helps adults with borderline resectable pancreatic cancer that has a KRAS G12D mutation.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT07240766

• Nimotuzumab plus Adebrelimab with chemotherapy for cisplatin‑ineligible head and neck cancer

  This trial will try combining nimotuzumab and adebrelimab with chemotherapy to see if the regimen is safe and helps people with recurrent or metastatic head and neck squamous cell carcinoma who cannot receive high‑dose cisplatin.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07105592

• Iparomlimab and Tuvonralimab plus nimotuzumab for recurrent or metastatic nasopharyngeal carcinoma after first-line treatment failure

  This will try combining two immune-targeting drugs, iparomlimab and tuvonralimab, with the antibody nimotuzumab to see if it helps people with recurrent or metastatic nasopharyngeal cancer whose first-line cisplatin-based treatment has failed.

  Recruiting Phase 2 Sun Yat-sen University · Guangdong · NCT07101744

• Combination therapies for PD-1–resistant recurrent or metastatic nasopharyngeal cancer

  This trial will try four different treatment regimens in people with recurrent or metastatic nasopharyngeal cancer who no longer respond to anti‑PD‑1 therapy after prior platinum chemotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07070479

• Nimotuzumab combined with chemoradiotherapy for elderly patients with esophageal cancer

  This study is testing if adding a new drug called nimotuzumab to standard treatment helps older patients with advanced esophageal cancer feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing · NCT06988956

• Nimotuzumab with nab-paclitaxel and gemcitabine for EGFR-positive pancreatic cancer

  This study is testing if a new combination of Nimotuzumab with nab-paclitaxel and gemcitabine can help people with EGFR-positive pancreatic cancer live longer and stay cancer-free after surgery.

  Recruiting Phase 2 Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT06722911

• Combining Nimotuzumab, Sintilimab, and Chemotherapy for Advanced Esophageal Cancer

  This study is testing a new combination of two drugs and chemotherapy to see if it helps people with advanced esophageal cancer feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT06718205

• Focused radiation plus nimotuzumab followed by tislelizumab for oligoprogressive recurrent or metastatic nasopharyngeal cancer after prior immunotherapy

  This trial will try focused stereotactic radiation together with the antibody nimotuzumab, followed by the PD‑1 drug tislelizumab, in people whose recurrent or metastatic nasopharyngeal cancer has progressed at 1–5 spots after prior anti–PD‑1 treatment.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT06676722

• Nimotuzumab with toripalimab plus gemcitabine/cisplatin for first-line recurrent or metastatic nasopharyngeal carcinoma

  This trial tests whether adding nimotuzumab to toripalimab with gemcitabine and cisplatin helps people with first-line recurrent or metastatic nasopharyngeal carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06509009

• Nimotuzumab with Chemoradiotherapy for Esophageal Cancer

  This study is testing if a combination of a new antibody treatment, chemotherapy, and radiation can help older or malnourished patients with advanced esophageal cancer feel better and improve their chances of recovery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06429839

• Nimotuzumab with Chemoradiotherapy for Unresectable Esophageal Cancer

  This study is testing if adding a new drug called nimotuzumab to chemotherapy and radiation can help patients with advanced esophageal cancer who haven't improved with earlier treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06410651

• Comparing two treatments for advanced nasopharyngeal carcinoma

  This study is testing a new combination treatment for advanced nasopharyngeal cancer to see if it works better than the standard treatment.

  Recruiting Phase 3 Air Force Military Medical University, China · Xi'an, Shaanxi · NCT06026878

• New treatments for advanced nasopharyngeal cancer with detectable EBV DNA after chemotherapy

  This study is testing if adding two new treatments, camrelizumab or nimotuzumab, to standard chemotherapy can help people with advanced nasopharyngeal cancer who still have detectable EBV DNA after their first round of treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05772208

• Nimotuzumab combined with chemotherapy and radiation for advanced nasopharyngeal cancer

  This study is testing if adding a new drug called nimotuzumab to chemotherapy and radiation can help people with advanced nasopharyngeal cancer feel better and improve their treatment outcomes.

  Recruiting at 9 sites Fourth Affiliated Hospital of Guangxi Medical University · Baise City, Guangxi and 8 other locations · NCT05717790

• Imaging EGFR-positive cancers using a new PET method

  This study is testing a new imaging method to see if it can help doctors spot certain cancers that have a lot of a protein called EGFR, which could help identify patients who might benefit from specific cancer treatments.

  Recruiting Phase 1/2 University of Saskatchewan · Saskatoon, Saskatchewan · NCT04235114

Quick answers

How many clinical trials of Nimotuzumab are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (20 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 3: 5, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →